Special Issue "Epigenetic Dysregulation in Cancer: From Mechanism to Therapy"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 30 September 2019
Assist. Prof. Dr. Angeliki Magklara
Laboratory of Clinical Chemistry, Faculty of Medicine, School of Health Sciences, University of Ioannina and Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Ioannina 45110, Greece.
Website | E-Mail
Interests: cancer epigenetics, cancer stem cells, breast cancer, tumor heterogeneity, epigenetic therapies
The advent of new technologies has allowed for the genome-wide identification of a plethora of epigenetic alterations across many tumor types. Recurrent mutations and/or skewed expression patterns of chromatin regulators promote an aberrant epigenome that is now regarded as a major contributing factor in carcinogenesis and not as a mere by-product of genomic instability in cancer cells. Moving beyond the basic cataloguing of epigenetic defects in cancer, the research community is focusing its efforts on revealing the pathogenic mechanisms that link perturbations in the epigenome to the development of the cancer phenotype. The task at hand is of increasing significance, considering the reversible nature of DNA methylation and histone modifications and the prospects for "epigenetic therapies" that have the potential to restore the normal epigenetic and transcriptional landscape. Developing such epigenetic agents is bound to be a demanding project, as we are just at the beginning of appreciating the technical challenges and the biological and clinical implications of drugging the cancer epigenome.
In this Special Issue, we invite original research papers and reviews that advance our mechanistic understanding of epigenetic dysregulation in cancer and how it can be exploited for the development of novel, promising therapeutic modalities.
Assist. Prof. Dr. Angeliki Magklara
Assoc. Prof. Dr. Tugba Bagci-Onder
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer epigenome
- DNA methylation
- histone modifications
- epigenetic regulators
- epigenetic therapies